• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Feature Selection in Predictive Modeling: A Systematic Study on Drug Response Heterogeneity for Type II Diabetic Patients.预测建模中的特征选择:关于II型糖尿病患者药物反应异质性的系统研究
AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:295-304. eCollection 2019.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.瑞格列奈:对其在2型糖尿病治疗中应用的药物经济学综述
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.
5
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.基于二甲双胍的不同降糖药物治疗 2 型糖尿病的疗效:一项纳入八项合格随机对照试验的网络荟萃分析。
J Cell Physiol. 2019 Mar;234(3):2795-2806. doi: 10.1002/jcp.27097. Epub 2018 Aug 26.
6
Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study.比较格列美脲、二甲双胍和罗格列酮单药治疗韩国初治 2 型糖尿病患者的疗效:降糖单药治疗研究的实际证据。
Diabetes Metab J. 2011 Feb;35(1):26-33. doi: 10.4093/dmj.2011.35.1.26. Epub 2011 Feb 28.
7
PARAMO: a PARAllel predictive MOdeling platform for healthcare analytic research using electronic health records.PARAMO:一个用于医疗保健分析研究的并行预测建模平台,使用电子健康记录。
J Biomed Inform. 2014 Apr;48:160-70. doi: 10.1016/j.jbi.2013.12.012. Epub 2013 Dec 25.
8
Robust clinical marker identification for diabetic kidney disease with ensemble feature selection.基于集成特征选择的糖尿病肾病稳健临床标志物识别。
J Am Med Inform Assoc. 2019 Mar 1;26(3):242-253. doi: 10.1093/jamia/ocy165.
9
A personalized prediction model for urinary tract infections in type 2 diabetes mellitus using machine learning.一种使用机器学习的2型糖尿病患者尿路感染个性化预测模型。
Front Pharmacol. 2024 Jan 5;14:1259596. doi: 10.3389/fphar.2023.1259596. eCollection 2023.
10
INFUSE: Interactive Feature Selection for Predictive Modeling of High Dimensional Data.
IEEE Trans Vis Comput Graph. 2014 Dec;20(12):1614-23. doi: 10.1109/TVCG.2014.2346482.

引用本文的文献

1
Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE).糖尿病血糖控制改善途径中的退伍军人事务部(VA)和非退伍军人事务部医疗中心参与者之间并发症、心血管风险因素和糖尿病管理的差异:一项比较效果研究(GRADE)。
Diabetes Res Clin Pract. 2022 Feb;184:109188. doi: 10.1016/j.diabres.2021.109188. Epub 2021 Dec 28.

本文引用的文献

1
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.与 2 型糖尿病和高心血管风险患者的血糖治疗降低或增加死亡率相关的特征:ACCORD 试验的机器学习分析。
Diabetes Care. 2018 Mar;41(3):604-612. doi: 10.2337/dc17-2252. Epub 2017 Dec 26.
2
Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.糖尿病心血管风险控制行动(ACCORD)试验中糖化血红蛋白目标未达到<8.0%的相关因素。
Diabetes Obes Metab. 2016 Jan;18(1):92-5. doi: 10.1111/dom.12569. Epub 2015 Oct 26.
3
An experimental comparison of feature selection methods on two-class biomedical datasets.两类生物医学数据集上特征选择方法的实验比较。
Comput Biol Med. 2015 Nov 1;66:1-10. doi: 10.1016/j.compbiomed.2015.08.010. Epub 2015 Aug 24.
4
Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness.糖尿病前期和2型糖尿病的异质性:对预测、预防及治疗反应性的影响
Curr Diabetes Rev. 2016;12(1):30-41. doi: 10.2174/1573399811666150416122903.
5
Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.患者特征与达格列净的临床重要差异反应无关:3期数据的阶段性分析
Diabetes Ther. 2014 Dec;5(2):471-82. doi: 10.1007/s13300-014-0090-y. Epub 2014 Dec 12.
6
A risk assessment model for type 2 diabetes in Chinese.中国2型糖尿病风险评估模型
PLoS One. 2014 Aug 7;9(8):e104046. doi: 10.1371/journal.pone.0104046. eCollection 2014.
7
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.在ACCORD试验中,随机分配至强化血糖控制对老年人与年轻人不良事件、心血管疾病及死亡率的影响。
Diabetes Care. 2014;37(3):634-43. doi: 10.2337/dc13-1545. Epub 2013 Oct 29.
8
Metformin: an old but still the best treatment for type 2 diabetes.二甲双胍:一种古老但仍然是治疗 2 型糖尿病的最佳药物。
Diabetol Metab Syndr. 2013 Feb 15;5(1):6. doi: 10.1186/1758-5996-5-6.
9
Multiple imputation by chained equations: what is it and how does it work?多重链结方程插补法:是什么,以及它如何运作?
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9. doi: 10.1002/mpr.329.
10
A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity.2 型糖尿病治疗反应评估:患者异质性的作用研究综述。
Diabetes Obes Metab. 2010 Oct;12(10):845-57. doi: 10.1111/j.1463-1326.2010.01248.x.

预测建模中的特征选择:关于II型糖尿病患者药物反应异质性的系统研究

Feature Selection in Predictive Modeling: A Systematic Study on Drug Response Heterogeneity for Type II Diabetic Patients.

作者信息

Chou Jingyuan, Flory James, Wang Fei

机构信息

Department of Healthcare Policy and Research. Weill Cornell Medicine.

出版信息

AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:295-304. eCollection 2019.

PMID:31258982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6568100/
Abstract

With the rapid development of computer hardware and software technologies, more and more electronic health data from insurance claims, clinical trials and hospitals are becoming readily available. These data provide a rich resource for developing various healthcare analytics algorithms, among which predictive modeling is of key importance in many real health problems. One important issue for data-driven predictive modeling is high dimensionality, and feature selection is one effective strategy to reduce the number of independent variables and control the confounding factors. However, most of the existing studies just pick one feature selection approach without comprehensive investigations. In this paper, we investigate the issue of drug response heterogeneity for type II diabetes mellitus (T2DM) patients using a large scale clinical trial data. Our goal is to find out the important factors that may lead to the response heterogeneity for three popular T2DM drugs, Metformin, Rosiglitazone and Glimepiride. We implemented 8 different feature selection approaches and compared their performances with various measures including prediction error and the consistency of the identified important factors. Finally, we ensemble all factor lists picked by different algorithms and obtain a final set of factors that contribute to the drug response heterogeneities and verified them through existing literature.

摘要

随着计算机硬件和软件技术的快速发展,越来越多来自保险理赔、临床试验和医院的电子健康数据变得易于获取。这些数据为开发各种医疗分析算法提供了丰富的资源,其中预测建模在许多实际健康问题中至关重要。数据驱动的预测建模的一个重要问题是高维度,而特征选择是减少自变量数量和控制混杂因素的一种有效策略。然而,大多数现有研究只采用一种特征选择方法,没有进行全面的调查。在本文中,我们使用大规模临床试验数据研究2型糖尿病(T2DM)患者的药物反应异质性问题。我们的目标是找出可能导致三种常用T2DM药物(二甲双胍、罗格列酮和格列美脲)反应异质性的重要因素。我们实施了8种不同的特征选择方法,并通过包括预测误差和所识别重要因素的一致性等各种指标比较了它们的性能。最后,我们整合了不同算法挑选出的所有因素列表,得到了一组导致药物反应异质性的最终因素,并通过现有文献对其进行了验证。